CPW
GILD icon

Crestmont Private Wealth’s Gilead Sciences GILD Stock Holding History

Crestmont Private Wealth’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$507K Buy
3,636
+302
+9% +$42.3K 0.16% 57
2025
Q4 		$409K Buy
3,334
+162
+5% +$19.7K 0.13% 54
2025
Q3 		$352K Buy
3,172
+273
+9% +$31K 0.12% 58
2025
Q2 		$321K Sell
2,899
-703
-20% -$74.8K 0.12% 54
2025
Q1 		$404K Buy
3,602
+56
+2% +$5.78K 0.17% 44
2024
Q4 		$328K Sell
3,546
-621
-15% -$55.9K 0.15% 47
2024
Q3 		$349K Buy
4,167
+30
+0.7% +$2.29K 0.15% 53
2024
Q2 		$284K Buy
+4,137
New +$276K 0.14% 59

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Crestmont Private Wealth's GILD Position: Q1 2026 in Review

Crestmont Private Wealth increased its Gilead Sciences (GILD) stake by 9.1% in Q1 2026, buying an estimated $42.3K and bringing the position to 3,636 shares worth $507K. The position accounts for 0.16% of the portfolio, ranked #57.

Crestmont Private Wealth first reported a position in GILD in Q2 2024 and has held it in 8 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Crestmont Private Wealth held 3,636 shares of Gilead Sciences worth $507K as of Q1 2026.
  • Crestmont Private Wealth bought 302 Gilead Sciences shares in Q1 2026, an estimated $42.3K.
  • Gilead Sciences made up 0.16% of Crestmont Private Wealth's portfolio in Q1 2026, its #57 holding.
  • Crestmont Private Wealth first reported a position in Gilead Sciences in Q2 2024 and has held it in 8 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Crestmont Private Wealth's 13F filing for Q1 2026, filed 8 May 2026.